Playback speed
10 seconds
SGO 2024 Insights: "COMB1NE Study - Characteristics and Real-World Outcomes of Epithelial Ovarian Cancer Patients Who Received Niraparib + Bevacizumab 1L Maintenance Therapy"
By
Insights from 2024 SGO Annual Meeting
FEATURING
Premal Thaker
By
Insights from 2024 SGO Annual Meeting
FEATURING
Premal Thaker
0 views
April 30, 2024
Comments 0
Login to view comments.
Click here to Login